Lippuner, Kurt

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

Bone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiński, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., et al. (2017) · The Lancet Diabetes & Endocrinology

Bone health and osteoporosis researchBone health and treatments

Cited by 996

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., et al. (2012) · Journal of Bone and Mineral Research

Bone health and osteoporosis researchBone health and treatments

Cited by 700

Fracture risk and zoledronic acid therapy in men with osteoporosis

Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., et al. (2012) · New England Journal of Medicine

Bone health and osteoporosis researchBone health and treatments

Cited by 359

FRAME Study: The Foundation Effect of Building Bone with 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab

Cosman, F., Crittenden, D. B., Ferrari, S., Khan, A., Lane, N. E., Lippuner, K., Matsumoto, T., Milmont, C. E., Libanati, C., & Grauer, A. (2018) · Journal of Bone and Mineral Research

Bone health and osteoporosis researchBone health and treatments

Cited by 175